Daol Investment Securities raises SK Biopharmaceuticals' target price to 160,000 won on Opakalim value

SK Biopharmaceuticals has received a boost in its valuation, with Daol Investment Securities raising its target stock price to 160,000 won. This upward revision reflects the firm's positive assessment of the company's strengthened product portfolio, particularly following the introduction of a new epilepsy treatment.

The brokerage firm maintained its 'BUY' investment rating for SK Biopharmaceuticals, signaling confidence in the company's future prospects. The new target price represents a significant increase from the previous 150,000 won target and stands in stark contrast to the stock's closing price of 91,600 won on the preceding day.

The key driver behind this optimistic outlook is the company's recent agreement with Biohaven Bioscience concerning a new epilepsy drug candidate, identified as Opakalim. This collaboration is expected to enhance SK Biopharmaceuticals' offerings in the neurological disorder market.